Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China

  • Chunhong Hu (Contributor)
  • Chunhong Hu (Contributor)
  • Ping Zhong (Contributor)
  • Yajing Wen (Contributor)
  • Yong Yang (Contributor)
  • Xiangyu Chen (Contributor)
  • Xiangyu Chen (Contributor)



<div>Objective:<p>To compare the efficacy of 3/4-drugs’ group with 1-drug’s or 2-drugs’ groups in coronavirus disease 2019 (COVID-19).</p>Methods:<p>We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs.</p>Results:<p>The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug’s or 2-drugs’ groups (P < 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug’s or 2-drugs’ groups (both were 9 days) (P < 0.001). The patients’ discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug’s or 2 drugs’ group (P < 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P < 0.05).</p>Conclusion:<p>The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients’discharge.</p></div>
Date made available1 Jan 2020
PublisherFigshare - Sage

Cite this